Skip to main content

Advertisement

SpringerLink
Log in

Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.

    Google Scholar 

  2. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6:569–79.

    Article  PubMed  CAS  Google Scholar 

  3. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48:964–70.

    Article  PubMed  CAS  Google Scholar 

  4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  PubMed  CAS  Google Scholar 

  5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  PubMed  CAS  Google Scholar 

  6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  PubMed  CAS  Google Scholar 

  7. Votrient EMA label. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf accessed 31 March 2011.

  8. Sutent EMA label http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf accessed 31 March 2011.

  9. Nexavar FDA label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s011lbl.pdf accessed 31 March 2011.

  10. Nexavar EMA label. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf accessed 31 March 2011.

  11. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. 2011;22:1812–23.

    Article  PubMed  CAS  Google Scholar 

  12. Abou-Alfa G, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA. 2010;304:2154–60.

    Article  PubMed  CAS  Google Scholar 

  13. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67:751–64.

    Article  PubMed  CAS  Google Scholar 

  14. Snow H BA, Gelder M, Voliotis D, Kelley S: Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Annals of Oncology 2008;19.

  15. Valsuani C, Siclari O, Camerini A, Canale ML, Rondini M, Donati S, et al. Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases J. 2009;2:9133.

    Article  PubMed  Google Scholar 

  16. Kamada P, Dudek AZ. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest. 2010;28:501–4.

    Article  PubMed  CAS  Google Scholar 

  17. Wong MK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009;29:473–8.

    Article  PubMed  CAS  Google Scholar 

  18. Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther. 2009;47:61–4.

    PubMed  CAS  Google Scholar 

  19. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep. 2010;12:102–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy

    Rodolfo Sacco, Marco Bertini, Antonio Romano, Emanuele Tumino & Giampaolo Bresci

  2. Department of Diagnostic and Interventional Radiology, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy

    Irene Bargellini, Barbara Ginanni, Elena Bozzi, Valentina Battaglia & Carlo Bartolozzi

  3. Institute of Internal Medicine, University of Foggia, Viale Pinto, 71100, Foggia, Italy

    Rodolfo Sacco & Emanuele Altomare

  4. Institute of Cardiology, University of Foggia, Viale Pinto, 71100, Foggia, Italy

    Matteo Di Biase

Authors
  1. Rodolfo Sacco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irene Bargellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Ginanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Bertini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Bozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emanuele Altomare
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valentina Battaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Emanuele Tumino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Matteo Di Biase
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giampaolo Bresci
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carlo Bartolozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rodolfo Sacco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sacco, R., Bargellini, I., Ginanni, B. et al. Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient. J Gastrointest Canc 43 (Suppl 1), 89–92 (2012). https://doi.org/10.1007/s12029-011-9328-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-011-9328-3

Keywords

Search

Navigation